Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

NCT04116918 · clinicaltrials.gov ↗
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Baodong Qin